| Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma J Long, A Wang, Y Bai, J Lin, X Yang, D Wang, X Yang, Y Jiang, H Zhao EBioMedicine 42, 363-374, 2019 | 272 | 2019 |
| Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers J Mao, D Wang, J Long, X Yang, J Lin, Y Song, F Xie, Z Xun, Y Wang, ... Journal for Immunotherapy of Cancer 9 (12), 2021 | 143 | 2021 |
| Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma J Lin, XU Yang, J Long, S Zhao, J Mao, D Wang, Y Bai, J Bian, L Zhang, ... Hepatobiliary surgery and nutrition 9 (4), 414, 2020 | 119 | 2020 |
| DNA methylation-driven genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma J Long, P Chen, J Lin, Y Bai, X Yang, J Bian, Y Lin, D Wang, X Yang, ... Theranostics 9 (24), 7251, 2019 | 106 | 2019 |
| Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for hepatocellular carcinoma J Long, Y Bai, X Yang, J Lin, X Yang, D Wang, L He, Y Zheng, H Zhao Cancer cell international 19, 1-12, 2019 | 100 | 2019 |
| Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression Y Bai, J Long, Z Liu, J Lin, H Huang, D Wang, X Yang, F Miao, Y Mao, ... Journal of cellular physiology 234 (10), 18837-18848, 2019 | 99 | 2019 |
| Alterations in DNA damage repair genes in primary liver cancer J Lin, J Shi, H Guo, X Yang, Y Jiang, J Long, Y Bai, D Wang, X Yang, ... Clinical Cancer Research 25 (15), 4701-4711, 2019 | 97 | 2019 |
| Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies D Wang, J Lin, X Yang, J Long, Y Bai, X Yang, Y Mao, X Sang, S Seery, ... Journal of hematology & oncology 12, 1-21, 2019 | 69 | 2019 |
| Therapeutic effects of resveratrol in a mouse model of LPS and cigarette smoke-induced COPD J Chen, X Yang, W Zhang, D Peng, Y Xia, Y Lu, X Han, G Song, J Zhu, ... Inflammation 39, 1949-1959, 2016 | 53 | 2016 |
| Mutational spectrum and precision oncology for biliary tract carcinoma J Lin, Y Cao, X Yang, G Li, Y Shi, D Wang, J Long, Y Song, J Mao, F Xie, ... Theranostics 11 (10), 4585, 2021 | 52 | 2021 |
| Transcriptional landscape of cholangiocarcinoma revealed by weighted gene coexpression network analysis J Long, S Huang, Y Bai, J Mao, A Wang, Y Lin, X Yang, D Wang, J Lin, ... Briefings in Bioinformatics 22 (4), bbaa224, 2021 | 51 | 2021 |
| Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy X Yang, H Xu, B Zuo, X Yang, J Bian, J Long, D Wang, J Zhang, C Ning, ... Hepatobiliary Surgery and Nutrition 10 (4), 434, 2021 | 50 | 2021 |
| T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy J Bian, J Lin, J Long, X Yang, X Yang, X Lu, X Sang, H Zhao American journal of cancer research 10 (12), 4585, 2020 | 50 | 2020 |
| Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: a retrospective, real-world study conducted in China DX Wang, X Yang, JZ Lin, Y Bai, JY Long, XB Yang, S Seery, HT Zhao World Journal of Gastroenterology 26 (30), 4465, 2020 | 41 | 2020 |
| Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy J Long, D Wang, X Yang, A Wang, Y Lin, M Zheng, H Zhang, X Sang, ... BMC medicine 19, 1-14, 2021 | 36 | 2021 |
| The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study D Wang, X Yang, J Long, J Lin, J Mao, F Xie, Y Wang, Y Wang, Z Xun, ... Frontiers in Oncology 11, 646979, 2021 | 36 | 2021 |
| A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape J Long, D Wang, A Wang, P Chen, Y Lin, J Bian, X Yang, M Zheng, ... Genome medicine 14 (1), 20, 2022 | 31 | 2022 |
| LncRNA CYTOR affects the proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells by regulating the miR-125b-5p/KIAA1522 axis B Hu, XB Yang, X Yang, XT Sang Aging (Albany NY) 13 (2), 2626, 2021 | 31 | 2021 |
| Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma X Yang, D Wang, J Lin, X Yang, H Zhao The Lancet Oncology 21 (9), e412, 2020 | 31 | 2020 |
| Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients X Yang, B Chen, Y Wang, Y Wang, J Long, N Zhang, J Xue, Z Xun, ... Hepatology International 17 (3), 709-719, 2023 | 26 | 2023 |
Haitao ZhaoPeking Union Medical College Hospital在 pumch.cn 的电子邮件经过验证
